Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. October 14, 2025 Efficacy of erdafitinib before or after enfortumab vedotin ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Perspectives on the Urological Care in Parkinson’s Disease Patients - Beyond the Abstract ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas was host to the Abstract/Posters Session. Dr Joaquim Bellmunt presented the disease-free survival and overall ...

E David Crawford interviews Jason Efstathiou about the PARTIQoL trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou presents the study's design ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon patients, and safety defined as non-inferiority in rectal and procedure-related ...

(UroToday.com The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Beth Neilsen ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...